A vast body of research in breast cancer prognostication has accumulated. Yet despite this, patients within current prognostic categories may have significantly different outcomes. There is a need to more accurately divide those cancer types associated with an excellent prognosis from those requiring more aggressive therapy. Gene expression array studies have revealed the numerous molecular breast cancer subtypes that are associated with differing outcomes. Furthermore, as next generation technologies evolve and further reveal the complexities of breast cancer, it is likely that existing prognostic approaches will become progressively refined. Future prognostication in breast cancer requires a morphomolecular, multifaceted approach involving the assessment of anatomical disease extent and levels of protein, DNA and RNA expression. One of the major challenges in prognostication will be the integration of potential assays into existing clinical systems and identification of appropriate patient subgroups for analysis.
ASJC Scopus subject areas
- Molecular Medicine
- Molecular Biology
- Pathology and Forensic Medicine
Boyle, D. P., McCourt, C. M., Matchett, K. B., & Salto-Tellez, M. (2013). Molecular and clinicopathological markers of prognosis in breast cancer. Expert review of molecular diagnostics, 13(5), 481-498. https://doi.org/10.1586/erm.13.29